EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma

Hideki Goto, Satoshi Ito, Masahiro Kizaki, Masaki Yamaguchi, Noriko Fukuhara, Koji Kato, Toko Saito, Yasuhito Terui, Tomomi Soshin, Natsuko Satomi-Tsushita, Hideyuki Honda, Chen Qian und 1 weitere

International Journal of Clinical Oncology · 2025

DOI: 10.1007/s10147-025-02865-4 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Hideki Goto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hokkaido University Hospital, Kita-14, Nishi-5, Kita-ku, Sapporo-shi, Hokkaido, 060-8648, Japan. hidekigt0220@gmail.com. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) face a poor prognosis in the absence of effective treatment options. Ibrutinib plus venetoclax demonstrated high response rates and a tolerable safety profile in the primary analysis of the Phase 2, M20-075 study (NCT04477486) in Japanese patients with R/R MCL. We report updated efficacy and safety from this study with longer follow-up.

Methods

Patients received 560 mg ibrutinib and 400 mg venetoclax (5-week ramp-up to 400 mg) once daily for up to 104 weeks followed by ibrutinib monotherapy. Primary endpoint was Independent Review Committee-assessed complete response (CR) rate. Secondary endpoints included overall response rate (ORR), duration of response (DOR), undetectable minimal residual disease (uMRD) in patients achieving CR, progression-free survival (PFS), overall survival (OS), and safety.

Results

After a median follow-up of 37.2 months, 13 patients had received ibrutinib plus venetoclax, 8 (62%) remained on ibrutinib monotherapy, and 9 (69%) completed 24 months of venetoclax. ORR was 83% (10/12 [per-protocol population]; all CR); median DOR was not reached. All 6 patients positive for MRD at baseline who achieved CR had uMRD. Median PFS and OS were not reached. Most frequent Grade ≥ 3 treatment-emergent adverse events (TEAEs) were neutropenia (46%) and leukopenia (23%); one TEAE leading to treatment discontinuation was squamous cell carcinoma unrelated to treatment. There were no cases of tumor lysis syndrome or TEAEs leading to death.

Conclusion

Long-term follow-up of ibrutinib plus venetoclax showed prolonged efficacy and a well-tolerated safety profile in Japanese patients with R/R MCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellSulfonamidesBridged Bicyclo Compounds, HeterocyclicAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalHumansAdenineFemaleMaleAgedPiperidinesMiddle AgedAged, 80 and overJapanTreatment OutcomeProgression-Free SurvivalAdultEast Asian People

Stichwörter der Autor:innen

IbrutinibMantle cell lymphomaRelapsed/refractoryVenetoclax

Substanzen

ibrutinibvenetoclaxAdenineSulfonamidesPiperidinesBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Hokkaido University Hospital, Kita-14, Nishi-5, Kita-ku, Sapporo-shi, Hokkaido, 060-8648, Japan. hidekigt0220@gmail.com.
  • Yamagata University Hospital, Yamagata, Japan.
  • Saitama Medical Center, Saitama Medical University, Saitama, Japan.
  • Ishikawa Prefectural Central Hospital, Ishikawa, Japan.
  • Tohoku University Hospital, Miyagi, Japan.
  • Kyushu University Hospital, Fukuoka, Japan.

Zitieren

APA

Goto, H., Ito, S., Kizaki, M., Yamaguchi, M., Fukuhara, N., Kato, K., Saito, T., Terui, Y., Soshin, T., Satomi-Tsushita, N., Honda, H., Qian, C., & Izutsu, K. (2025). Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02865-4

Vancouver

Goto H, Ito S, Kizaki M, Yamaguchi M, Fukuhara N, Kato K, et al. Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02865-4

BibTeX
@article{Goto2025,
  author = {Goto, Hideki and Ito, Satoshi and Kizaki, Masahiro and Yamaguchi, Masaki and Fukuhara, Noriko and Kato, Koji and Saito, Toko and Terui, Yasuhito and Soshin, Tomomi and Satomi-Tsushita, Natsuko and Honda, Hideyuki and Qian, Chen and Izutsu, Koji},
  title = {Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1007/s10147-025-02865-4}
}
Kostenlos starten →